May 20, 2013 | bioresearchonline.com
MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) is pleased to announce the filing of a U.S. patent application concerning methods and formulations to achieve targeted tumor cell death. MCT-485 is a noncoding double...
Read more...
MultiCell MCT-485 tumor patent micro cell targeted carcinoma miRNAs
May 20, 2013 | envita.com
A large number of cancer and Stage 4 cancer patients will look at statistical outcomes when choosing the optimal treatment facility, but as you will learn, statistics can be misleading. This article goes far beyond the numbers,...
Read more...
cancer treatment patient immunotherapy SEER therapy Stage radiation Envita Vitamin C statistics chemotherapy conventional
May 21, 2013 | augusta.com
She came to establish a Department of Radiation Oncology at Georgia Regents University, but Dr. Feng-Ming Kong believes it could soon become part of a therapy at the GRU Cancer Center that is not available anywhere else. Many...
Read more...
Kong radiation therapy tumor oncology personalize medicine GRU immune treatment dose cancer Oncology
May 20, 2013 | dailyherald.com
Despite the advances made against many types of cancer, pancreatic cancer remains grimly resistant to treatment. Only about 4 percent of patients survive for five years, mainly because of the disease's vicious ability to...
Read more...
cell tumor Gravekamp bacterium cancer Listeria immune metastatic microbe radioactive mouse Gorelick pancreatic Dadachova radiation Listeria-based tissue
May 20, 2013 | qualitystocks.net
When Zacks Small Cap Research came out with their positive evaluation of Advaxis, a biotech company using Listeria bacteria to develop immunotherapies for the treatment of cancer, the focus was on the encouraging results the...
Read more...
Advaxis cancer ADXS-HPV Phase immunotherapy cell vaccine cervical
May 20, 2013 | finanznachrichten.de
Press release 130520 Immunicum AB (publ) presents a status update with promising data from an ongoing clinical phase I/II-study of the cancer vaccine INTUVAX' in the treatment of metastatic renal c...
Read more...
Globenewswire Immunicum INTUVAX vaccine cancer AB kidney promising
May 21, 2013 | checkorphan.org
King's College Hospital have launched the first trial of the DCVax® therapy in Europe which is already significantly extending life for patients in a US trialThe brain cancer trial uses the patient's tumour to develop their own...
Read more...
vaccine Glioblastoma patient trial King cancer brain DCVax tumor immune personalized launch therapy Europe laura.carpenter mulltiforme
May 20, 2013 | firmenpresse.de
Peregrine Pharmaceuticals Reaches Agreement With FDA on a Phase III Trial Design for Bavituximab in Second-Line Non-Small Cell Lung Cancer PressRelease by Peregrine Pharmaceuticals Phase III Registration Trial of...
Read more...
Peregrine Bavituximab trial Phase III clinical cancer FDA Pharmaceuticals
May 20, 2013 | prostate.net
Immunotherapy and Prostate Cancer In order to understand prostate cancer and immunotherapy treatment, you need to learn a little bit about the progression and standard treatment of prostate cancer. In the United States,...
Read more...
All similar articles: 110 »
prostate immunotherapy cancer therapy immune Provenge androgen treatment
May 20, 2013 | medicaldaily.com
With the uncovered risk of melanoma for patients with inflammatory bowel disease, researchers advise these individuals to apply sunscreen, among other sun-protective measures. Patients living with inflammatory bowel disease...
Read more...
IBD melanoma inflammatory bowel immune Mayo disease cancer patient risk skin 37
May 20, 2013 | pharmaceutical-business-review.com
PBR Staff Writer Published 20 May 2013 ImmunoCellular Therapeutics has obtained US patent for methods of use of interleukin 13-receptor alpha 2 protein (IL-13Rα2) in cancer immunotherapy. IL-13 is an immune regulatory cytokine...
Read more...
13-receptor ImmunoCellular interleukin IL-13Ra2 patent alpha protein covering obtain antigen US
May 20, 2013 | fortmilltimes.com
Ignyta, Inc. announced today that it has acquired Actagene Oncology, Inc., effective May 20, 2013. Actagene was a San Diego based privately held biotechnology company founded in February 2013 that was developing personalized...
Read more...
Ignyta Actagene oncology cancer personalize medicine
May 20, 2013 | heraldtribune.com
WANT A HEALTHIER HEART? TRY GETTING YOURSELF A DOG The nation’s largest cardiovascular health organization has a new message for Americans: Owning a dog may protect you from heart disease. The unusual message was in a...
Read more...
immune blood pressure heart healthy study decrease hypertensive cardiovascular drug tumor dog IN Herrmann-Lingen researcher pet Fidelity New York Times
May 20, 2013 | sectorpublishingintelligence.co.uk
Argos Therapeutics to Present at the Sachs Cancer Bio Partnering ForumDURHAM, N.C., May 20, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully...
Read more...
Argos cancer immunotherapy Arcelis Therapeutics Sachs dendritic Arcelis™ infectious personalized theruthgroup.com Plessinger disease commercialization treatment present
May 20, 2013 | finanznachrichten.de
BETHESDA, Md., May 20, 2013 /PRNewswire/ --TNI BioTech, Inc. (OTCQB: TNIB), a biotech company combating fatal diseases through the activation and mobilization of the body's immunesystem using patented immunotherapy, announced...
Read more...
BioTech TNI OTCQB TNIB immunotherapy immune marketplace disease Inc. forward-looking stock trading
May 20, 2013 | therebel.org
In the first study of its kind, researchers with the University of Manchester found that Omega-3 fats could help to increase your skin’s immunity to cancer and infection. Who would have thought that some fatty fish could keep...
Read more...
Omega-3 cancer fat infection study skin protect fish fatty immunosuppression immunity Dermatology
May 20, 2013 | drugs.com
Phase III data from the CLL11 study to be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) GA101 plus chlorambucil more than doubled the length of time during which the disease did not get...
Read more...
GA101 chlorambucil Roche CLL11 MabThera Rituxan CLL disease
May 20, 2013 | fortmilltimes.com
PRELIMINARY PROXY STATEMENT FOR MERGER FILED WITH SEC Regulatory News: EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) today announced operating and financial results for the three months ended March 31,...
Read more...
EpiCept Immune Ceplene AmiKet™ merger proxy 2013 quarter
May 20, 2013 | drugs.com
SHM-XEL platform to generate high thermostability antibodies for biodefense applications SAN DIEGO, May 16, 2013 /PRNewswire/ -- AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced the receipt of a...
Read more...
AnaptysBio antibody SHM-XEL SHM anti-ricin therapeutic biodefense
May 19, 2013 | besthelpservices.com
The commercial mushroom is the most common of its kind that is used in the entire world. In the recent studies, they found out that the agaricus bisporus extract can be used as treatment for various health conditions. It can...
Read more...
Rosalind Landry Agaricus extract bisporus www.radiantlightnutrition.com kidney digestive study body benefit agaritine thus patient
May 18, 2013 | prostate.net
Does Provenge Work Better with Xtandi? Because treatments for castration-resistant prostate cancer have only been studied individually, it is not definitively possible to answer the question “Does Provenge work better with...
Read more...
Provenge Xtandi prostate Dendreon cancer
May 18, 2013 | danisfoundation.org
From http://marycrowley.org/en/Clinical%20Trials/Ewings%20Sarcoma.aspx Dani’s Foundation is pleased to support the Mary Crowley Cancer Research Center and their current clinical trial for Ewing’s Sarcoma. To find out more...
Read more...
Ewing Crowley clinical Mary cancer trial FANG Sarcoma patient vaccine marycrowley.org Ewings%20Sarcoma.aspx furin&GMCSF 972-566-6647 Clinical%20Trials immune www.marycrowley.org bi-shRNA Ghisoli immunosuppressor therapy
May 17, 2013 | checkorphan.org
MultiCell Technologies, Inc. is pleased to announce the filing of a U.S. patent application concerning methods and formulations to achieve targeted tumor cell death. MCT-485 is a noncoding double stranded micro RNA (miRNA)...
Read more...
MCT-485 MultiCell tumor patent micro cell targeted carcinoma miRNAs immune TACE cancer application noncoding Hepatocellular
May 17, 2013 | nanowerk.com
In the quest to develop anti-cancer vaccines that would stimulate the body to destroy tumors and keep them from recurring, researchers continually run into the same problem - the immune-stimulating proteins, known as antigens,...
Read more...
nanoparticles Kissenpfennig ovalbumin antigen dermis CD8-positive cell melanoma dendritic vaccine microneedles tumor ovalbumin-expressing immune protein B16 response
May 18, 2013 | prostate.net
Xofigo Compared to Provenge Xofigo compared to Provenge is a factor that men with prostate cancer may have to consider. The Food and Drug Administration (FDA) approved a new medication, Xofigo (radium-223 dichloride), for late...
Read more...
All similar articles: 257 »
Xofigo Provenge prostate cancer medication
May 17, 2013 | salon.com
That groundbreaking clinical trial in the New York Times? It's my study -- and I'm 15 months clean By The author (second from right), surrounded by her doctors I’ve spent my whole career trying to make some kind of a name for...
Read more...
All similar articles: 579 »
Katie McDonough cancer immunotherapy patient trial remarkable treatment truly truely tumor doctor drug durable cancer-free
May 17, 2013 | healthnewsreview.org
The following is a guest post by Harold DeMonaco, MS, one of our expert reviewers on HealthNewsReview.org, and a frequent guest blogger on this site. ———————- The American Society of Clinical Oncology (ASCO) will hold its...
Read more...
ASCO abstract immunotherapy melanoma ipilimumab study meeting drug headline cancer
May 17, 2013 | uoguelph.ca
Zafir Syed His Guelph undergrad degree first gave Zafir Syed a close-up look at the human brain. Now as a master’s student on his hometown campus, he hopes to help develop novel ways to treat brain cancer. Syed studies...
Read more...
brain vaccine cancer Syed tumor Zafir Guelph anatomy Bridle cell develop aim target treat undergrad immune
May 17, 2013 | prweb.com
Promising Study of CRS-207 Immunotherapy Hopes to Achieve Mesothelioma Remission. Dallas, TX (PRWEB) May 15, 2013 The Mesothelioma Research Foundation of America has announced Aduro BioTech’s initiation of Phase II human trials...
Read more...
CRS-207 mesothelioma PD-L1 PD-1 Budd cancer Baron&Budd immunotherapy Phase
May 17, 2013 | yahoo.com
May 17 2013, 07:25 by: John Tobey | includes: We had great news today (Thursday), but the response was tepid. Rather than being disappointed or dismissing the news, here is why we should be excited at both the developments and...
Read more...
John Tobey Merck Bristol-Myers drug Roche R&D cancer Pfizer long-term immunotherapy investor PD-L1 stock
